Form 4: Krystal Biotech CEO and Spouse Complete Pre-Planned Stock Sales

Krystal Biotech's President and CEO, Krish S. Krishnan, and his spouse have completed sales of Krystal Biotech common stock totaling 35,773 shares through pre-arranged Rule 10b5-1 trading plans.

Summary

• Krish S. Krishnan, President and CEO of Krystal Biotech, Inc., and his spouse, Suma M. Krishnan, completed sales of Krystal Biotech common stock between July 14, 2025, and July 16, 2025.
• These sales were executed under Rule 10b5-1 trading plans, which commenced on September 12, 2024, and were designed for quarterly sales of 25,000 shares of Common Stock each.
• Krish S. Krishnan directly sold a total of 17,873 shares at weighted average prices ranging from $150.00 to $151.79.
• Suma M. Krishnan, the spouse, indirectly sold a total of 17,900 shares at weighted average prices ranging from $150.00 to $151.79.
• Both Rule 10b5-1 trading plans have reached their maximum number of shares to be sold and have now terminated.
• Following these transactions, Krish S. Krishnan directly beneficially owns 1,508,056 shares, and indirectly owns 90,000 shares via the Krishnan Spousal Trust and 50,000 shares via the Krishnan Family Trust.
• Suma M. Krishnan indirectly beneficially owns 1,438,711 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive because the sales were conducted under pre-arranged 10b5-1 plans, which indicates a structured and transparent approach to insider selling rather than opportunistic or reactive sales. The termination of the plans also provides clarity.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it might suggest a lack of confidence, although this is mitigated by the 10b5-1 plan.

Risks

• Potential negative investor sentiment or misinterpretation of the sales as a lack of confidence, despite the pre-planned nature.

Future Outlook

NA

Industry Context

This Form 4 filing is a standard disclosure of insider trading activity, common across all publicly traded industries. It does not provide specific industry-related insights beyond the company's stock transactions.

Related Party Transactions

• Sales by Suma M. Krishnan, spouse of the Reporting Person, are reported as indirect beneficial ownership.
• Shares held by Krishnan Spousal Trust and Krishnan Family Trust, where the Reporting Person and spouse have joint beneficial ownership and control, represent related party holdings.

Stakeholder Impact

• Shareholders may interpret the sales as a signal, though the 10b5-1 plan mitigates negative implications. Transparency of the plan completion is positive.

Key Dates

Recommendation

Keywords

Krystal Biotech, KRYS, SEC Form 4, Insider Trading, Stock Sales, Rule 10b5-1 Plan, Executive Compensation, Beneficial Ownership, Corporate Governance